Literature DB >> 3899472

Multicenter evaluation of six methods for predicting warfarin maintenance-dose requirements from initial response.

W T Sawyer, T E Poe, B R Canaday, J S Weiner, D M Williams, C E Webb, M J Ellison.   

Abstract

Warfarin maintenance-dose requirements predicted by six mathematical methods based on initial response to therapy were compared with patients' actual dose requirements in a multicenter trial. Data were collected for patients who had received an initial regimen of warfarin sodium 10 mg orally every 24 hours for three days and for whom a prothrombin time (PT) had been determined 16-20 hours after the third dose. Patients' individual dose requirements and PT values were recorded during one to three follow-up visits after discharge from one of seven medical centers. Prothrombin ratios (patient PT divided by control PT) calculated on day 4 were used for maintenance-dose prediction by five methods; a sixth method was based on the cumulative warfarin dose-PT response curve up to a PT value of 20 seconds. For 54 men and 30 women who qualified for the study, 197 maintenance-dose-PT response measurements were recorded; 95 in the first four weeks of therapy, 76 during weeks 5-12, and 26 at 6-12 months after initial treatment. Prothrombin ratios were within the therapeutic range (PT 1.5-2.5 times the control value) in 154 observations, and the mean actual warfarin sodium maintenance dose associated with therapeutic response was 7.6 mg/day. For patients with therapeutic prothrombin ratios, dose predictions by the five methods using prothrombin ratios (PRs) correlated significantly with actual dose requirements. The formula that predicted doses numerically closest to the actual dose is as follows: Dose = 11.17 - 21.08 (log PR). Only 45 observations were obtained for the sixth prediction method, and the correlation between actual and predicted doses was not significant. Initial warfarin maintenance-dose requirements can be predicted effectively based on one PT determination after administration of three daily 10-mg doses.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899472

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  7 in total

1.  Dosage individualization of warfarin using artificial neural networks.

Authors:  Mohammad I Saleh; Sameh Alzubiedi
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

Review 2.  Control of warfarin therapy.

Authors:  D K Scott
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

3.  Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing.

Authors:  R H White; R Hong; A P Venook; M M Daschbach; W Murray; D R Mungall; R W Coleman
Journal:  J Gen Intern Med       Date:  1987 May-Jun       Impact factor: 5.128

Review 4.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

5.  The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient. Cefamandole, cefazolin, vancomycin.

Authors:  D M Angaran; V C Dias; K V Arom; W F Northrup; T G Kersten; W G Lindsay; D M Nicoloff
Journal:  Ann Surg       Date:  1987-08       Impact factor: 12.969

6.  Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

Authors:  Andrea L Jorgensen; Sameh Al-Zubiedi; Jieying Eunice Zhang; Andrew Keniry; Anita Hanson; Dyfrig A Hughes; Diane van Eker; Lisa Stevens; Karen Hawkins; Cheng H Toh; Farhad Kamali; Ann K Daly; David Fitzmaurice; Alison Coffey; Paula R Williamson; Brian Kevin Park; Panos Deloukas; Munir Pirmohamed
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

7.  Anticoagulation control with warfarin by junior hospital doctors.

Authors:  J Zatuchni
Journal:  J R Soc Med       Date:  1988-04       Impact factor: 18.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.